Lu-177 PSMA Therapy for Metastatic Prostate Cancer

Course overview

This on-line course, available to Nuclear Pharmacists 24/7/365, presents an overview of a radiopharmaceutical recently approved by the US Food and Drug Administration for radionuclide therapy of patients with castration-resistant metastatic prostate cancer. It contains a comprehensive tutorial in outline format along with a 20 question test that must be passed with a minimum score of 80%. This course will be submitted for CE Credit approval to the Florida Board of Pharmacy as well as the Society of Nuclear Medicine and Molecular Imaging. It will be suitable for Pharmacists, Nuclear Pharmacists, Pharmacy Technicians, and Nuclear Medicine Technologists.